Cardiovascular Systems Inc (CSI), a subsidiary of Abbott Laboratories, is a medical device company that develops and commercializes products for the treatment of peripheral and coronary vascular disease. The company's products include peripheral orbital atherectomy systems, coronary orbital atherectomy systems, crowns, and accessories. Its peripheral artery disease system is a percutaneous orbital atherectomy system that is used as therapy for OAS atherosclerotic disease in peripheral arteries. CSI offers accessories such as guide wires, lubricants, infusion pumps and ancillary products. It has developed orbital atherectomy systems technology for both peripheral and coronary commercial applications. The company serves patients suffering from peripheral arterial disease and coronary artery diseases. It markets its products through its network of distributors in the US to hospitals and clinics. CSI is headquartered in St. Paul, Minnesota, the US.
Cardiovascular Systems Inc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Coronary Orbital Atherectomy System | Diamondback 360 |
Peripheral Orbital Atherectomy System | Zilient |
Coronary Balloon Dilatation Catheter | Teleport |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Contracts/Agreements | In February, the company signed an agreement to be acquired by Abbott Laboratories. |
2023 | Others | In January, the company announced that Innova Vascular, Inc. (Innova) submitted a 510(k) Premarket Notification to the U.S. Food and Drug Administration (FDA) for its thrombectomy devices intended to treat peripheral vascular disease. |
2022 | New Products/Services | In October, the company announced the full market release of the 2.00 Max Crown for peripheral orbital atherectomy systems (2.00 Max Crown). |
Competitor Comparison
Key Parameters | Cardiovascular Systems Inc | Johnson & Johnson | Medtronic Plc | Asahi Kasei Corp | Becton Dickinson and Co |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | Ireland | Japan | United States of America |
City | St. Paul | New Brunswick | Dublin | Chiyoda-Ku | Franklin Lakes |
State/Province | Minnesota | New Jersey | - | Tokyo | New Jersey |
No. of Employees | 725 | 152,700 | 95,000 | 48,897 | 77,000 |
Entity Type | Private | Public | Public | Public | Public |
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Scott R. Ward | Chief Executive Officer; President; Chairman | Executive Board | 2016 | 62 |
Jeffrey S. Points | Chief Financial Officer | Senior Management | 2018 | 45 |
Sandra M. Sedo | Chief Compliance Officer | Senior Management | 2016 | 58 |
Jeffery W. Chambers, M.D | Chief Medical Officer | Senior Management | 2022 | - |
John M. Hastings | Executive Vice President - Operations and Technology | Senior Management | 2021 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer